Although numerous mechanisms have been suggested to be accountable for this phenomenon, including KIT gene amplification, the occurrence of additional point mutations seems to be the most recurrent event suggesting that imatinib secondary resistance in GIST could be dependent on a phenomenon not yet completely explored in terms of temporal development of the tumor [33]. The gene discussed is KIT; the disease is neoplasm.